Avita Medical (ASX:AVH) share price soars 23% as earnings stage a comeback

Shares in the regenerative medicine company are on the move today.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Avita Medical share price is up 23% today after the company released its financial results for a six-month 'transition period' to 31 December 2021
  • Earnings grew substantially and Avita has kicked off 2022 with a number of clinical trial updates 
  • In the last 12 months, the Avita Medical share price has collapsed more than 44% but is up 25% this week.

The Avita Medical Inc (ASX: AVH) share price is skyrocketing today after the company released its financial results for a six month "transition period" ended 31 December 2021.

The company announced in December 2021 that it wanted to change its fiscal year from June 30 to December 31. That's why Avita is reporting for a six-month period today.

At the time of writing, the Avita share price is 23% higher at $3.16.

Avita Medical share price surges as revenue spikes 37%

Key takeouts from the company's earnings results today:

  • Revenue increased 37% to $14 million, compared to $10.2 million the same time last year
  • Completed enrolment in two clinical trials with the goal of submitting premarket approval (PMA) supplements in 2022
  • Received FDA approval of the PMA supplement for Recell Autologous Cell Harvesting Device
  • Approved application for commercialisation of the Recell system in Japan
  • $55.5 million in cash and equivalents at the end of the period
  • $49.3 million in short-term and long-term marketable securities, with no debt.

What happened this period for Avita Medical?

The company recognised a 37% gain in revenue to $14 million, underscored by its Recell commercial revenues of $13.8 million. Recell is a system that allows medics to use a patient's own skin cells to produce 'spray-on' skin in the treatment of acute burns.

Avita also extended the shelf life of Recell and this led to a 300 basis point increase in gross profit margin to 86% compared with 83% last year.

It also saw a 7% increase in operating expenses due to "ongoing development of a next-generation automated skin preparation device, pre-commercialisation planning for Recell launches in soft tissue reconstruction and vitiligo, as well as increased hands-on professional education and training events".

The jump in revenue carried down vertically through Avita's P&L. The company's net loss decreased by $1.5 million to $14.4 million, helped by stronger margins as well.

As well, so far in 2022, the company has received approval of the PMA supplement for Recell in the US and was awarded an application for the commercialisation of Recell in Japan.

Management commentary

Speaking on the results, Avita CEO Dr Mike Perry said:

We are pleased with the terrific results that we are achieving with RECELL in US burn centres, as well as with our recent achievement of many key corporate milestones. Our success in burns will help us prepare for and is expected to increase our future adoption with respect to commercialisation in much larger markets for soft tissue reconstruction and vitiligo in the second half of 2023.

What's next for Avita?

Avita forecasts total revenues to grow by 20% year on year in CY22. It expects approximately $30 million at the top, with an additional $300,000 in contract revenues.

The company expects US BARDA contract revenues of approximately $0.3 million in 2022. That's down from $7.9 million last year, as several contract terms have been completed.

But the company is confident in its focus for the year ahead:

As we emerge from COVID-19, we expect further Recell adoption in US burn centers where we are focusing our commercial efforts. The adoption of Recell, and its positive patient outcomes and safety profile, positions us very well for broader commercial expansion planned for soft tissue reconstruction and vitiligo indications in the second half of 2023 following anticipated FDA approval.

Avita Medical share price snapshot

In the last 12 months, the Avita Medical share price has collapsed more than 44% and is down 9% this year to date.

However, during the past month of trading, the company's shares have soared 16% and, on today's results, are now more than 25% in the green this week alone.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Earnings Results

ASX 200 stock jumps 10% on strong FY24 results

How did this KFC restaurant operator perform in FY 2024?

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock just slashed its final dividend by 23%

This retailer had a tough time during the 12 months. Here's how it performed.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Earnings Results

Catapult shines: 20% sales growth propels ASX tech stock to new 52-week high

A strong annual result from this tech player has caught investor attention.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Earnings Results

Xero share price leaps 8% on staggering earnings upheaval

A major turnaround in profitability is sending investors into a frenzy over Xero shares today.

Read more »

a construction worker sits pensively at his desk with his arm propping up his chin as he looks at his laptop computer while wearing a hard hat and visibility vest in a bunker style construction shed.
Materials Shares

Which ASX 200 stock just plunged 12% despite record full-year earnings?

It looks like an impressive report card but UBS doesn't like the FY25 guidance.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

ASX 200 tech stock lifts off on another record-setting half-year profit

Investors are bidding up the ASX 200 tech company following its half-year results.

Read more »

increasing rural asx share price represented by happy looking sheep
Earnings Results

Why is this ASX All Ords stock staying strong as profits crash 76%

How is this company's share price marching higher after mowing down more than three-quarters of its profits compared to a…

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces as they react to the action in front of them in a home setting.
Earnings Results

Guess which ASX 200 stock is surging 11% on an 'outstanding' result

This ASX gaming giant just posted a 17% jump in profits, and its shareholders are basking in the glory.

Read more »